PRDM15 is a key regulator of metabolism critical to sustain B-cell lymphomagenesis
-
Published:2020-07-14
Issue:1
Volume:11
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Mzoughi Slim, Fong Jia Yi, Papadopoli David, Koh Cheryl M., Hulea LauraORCID, Pigini Paolo, Di Tullio FedericoORCID, Andreacchio Giuseppe, Hoppe Michal MarekORCID, Wollmann Heike, Low Diana, Caldez Matias J., Peng Yanfen, Torre Denis, Zhao Julia N., Uchenunu Oro, Varano Gabriele, Motofeanu Corina-Mihaela, Lakshmanan Manikandan, Teo Shun Xie, Wun Cheng Mun, Perini Giovanni, Tan Soo Yong, Ong Chee BingORCID, Al-Haddawi Muthafar, Rajarethinam Ravisankar, Hue Susan Swee-Shan, Lim Soon Thye, Ong Choon KiatORCID, Huang DachuanORCID, Ng Siok-Bian, Bernstein Emily, Hasson Dan, Wee Keng Boon, Kaldis PhilippORCID, Jeyasekharan AnandORCID, Dominguez-sola David, Topisirovic IvanORCID, Guccione Ernesto
Abstract
AbstractPRDM (PRDI-BF1 and RIZ homology domain containing) family members are sequence-specific transcriptional regulators involved in cell identity and fate determination, often dysregulated in cancer. The PRDM15 gene is of particular interest, given its low expression in adult tissues and its overexpression in B-cell lymphomas. Despite its well characterized role in stem cell biology and during early development, the role of PRDM15 in cancer remains obscure. Herein, we demonstrate that while PRDM15 is largely dispensable for mouse adult somatic cell homeostasis in vivo, it plays a critical role in B-cell lymphomagenesis. Mechanistically, PRDM15 regulates a transcriptional program that sustains the activity of the PI3K/AKT/mTOR pathway and glycolysis in B-cell lymphomas. Abrogation of PRDM15 induces a metabolic crisis and selective death of lymphoma cells. Collectively, our data demonstrate that PRDM15 fuels the metabolic requirement of B-cell lymphomas and validate it as an attractive and previously unrecognized target in oncology.
Funder
Center for Strategic Scientific Initiatives, National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference55 articles.
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5–29 (2015). 2. Campo et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117, 5019–5032 (2011). 3. Johnson, N. A. et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30, 3452–3459 (2012). 4. Ueda, C., Nishikori, M., Kitawaki, T., Uchiyama, T. & Ohno, H. Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma. Int. J. Hematol. 79, 52–54 (2004). 5. Haralambieva, E. et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am. J. Surg. Pathol. 29, 1086–1094 (2005).
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|